Small molecule · developed by Supernus Pharmaceuticals
SAGE-718 is an oral softgel lipid capsule formulation studied in Huntington's Disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05655520 | Phase 3 | Huntington's Disease | Terminated | SUPN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Huntington's Disease
Updated Nov 1, 2026. Something wrong or missing? Report it on the SUPN page.
See SUPN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SUPN catalysts and pipeline →